Clinical Trial Update: Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa [Phase 3]

View source ↗

Summary

Phase 3 trial of ALXN1850 versus placebo in adolescents and adults with hypophosphatasia who have not previously been treated with asfotase alfa; the study is c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypophosphatasia

Drugs mentioned

• ALXN1850 (ALXN1850)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Hypophosphatasia | Phase 3 | Status: ACTIVE_NOT_RECRUITING